ProCE Banner Activity

What Must Be Tested in NSCLC Today and Likely Tomorrow

Clinical Thought
Expert commentary by Drs Matthew Gubens, a thoracic oncologist, and Craig Mackinnon, an anatomical and molecular pathologist, on the current and emerging role and importance of biomarker testing in NSCLC.

Released: July 11, 2022

Expiration: July 10, 2023

No longer available for credit.

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Craig Mackinnon

Craig Mackinnon, MD, PhD

Professor
Direct Division of Genomic Diagnostics and BioInformatics
University of Alabama at Birmingham
Birmingham, Alabama

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Genentech TEXT Only

Janssen administered by Scientific Affairs

Lilly

Novartis Pharmaceuticals Corporation

Partners

AMP

ProCE Banner

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Genzyme/Sanofi, iTeos, Surface; researcher: Amgen, Celgene, Johnson & Johnson, Merck, Novartis, Trizell.

Craig Mackinnon, MD, PhD

Professor
Direct Division of Genomic Diagnostics and BioInformatics
University of Alabama at Birmingham
Birmingham, Alabama

Craig Mackinnon MD, PhD, has no relevant financial relationships to disclose.